An observational study in Myeloproliferative Neoplasm, sponsored by Weizmann Institute of Science. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Weizmann Institute of Science · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for invasive bone marrow biopsies.
PERIBLOOD-MPN is an observational, multi-center study that aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing (scRNA-seq). Current diagnostic practice relies on bone marrow (BM) biopsy, a procedure that is invasive, technically demanding, and may be inconclusive in early or prefibrotic disease stages.
Prior work in the field has established a reference atlas of healthy cHSPC subtypes and a computational pipeline capable of identifying disease-specific transcriptional changes by quantifying deviations from this reference. This study will assess whether PB-based genomic profiling can accurately distinguish MPN from non-clonal cytoses, including secondary erythrocytosis or thrombocytosis.
Patients referred for a bone marrow biopsy due to suspected myeloproliferative neoplasm (MPN) will undergo PB collection for genomic profiling. The primary objective is to develop a PB-based test by comparing the new test's diagnoses to conventional BM-based diagnostics. The secondary objectives include evaluating its potential for MPN subtype classification and risk stratification, as well as assessing its ability to reduce the need for BM biopsies.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
This study's planned enrollment of 500 is above the median of 150 across 115 observational studies indexed under Myeloproliferative Disorders.
Browse Myeloproliferative Disorders studies →Weizmann Institute of Science is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with MPN, or suspicion for MPN, who are referred to BM will be recruited to the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes:
Polycythemia Vera (PV) Criteria:
Essential Thrombocythemia (ET) Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observational intervation of cHSPCs
To development PERIBLOOD-MPN Diagnostic Test
Development of PERIBLOOD-MPN Diagnostic Test Using PB-Derived CD34+ cHSPCs for Diagnosis of MPN
Time frame: Three months following the PB sample
No study locations are listed for this record.
Plan to share: No — We will send PERIBLOOD report including the genetic data, for each patients, to the participating sites
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2029, 32 months later.
Of 37 observational studies under Myeloproliferative Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 62. This study's planned 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →
Weizmann Institute of Science